VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Tempero on Pancreatic Cancer Immunotherapies

Margaret A. Tempero, MD
Published: Monday, Nov 25, 2013

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.

Immunotherapies in this space is a work in progress, Tempero admits. Investigators at Johns Hopkins University School of Medicine have been looking at an autologous cell-based vaccine. Antigen-specific vaccines are in development in pancreatic cancer as well, Tempero says.

There is a need to “make room” for immunotherapies and determine their optimal use, especially with regard to immune checkpoint inhibitors, such as PD-1 and anti-CTLA-4.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.

Immunotherapies in this space is a work in progress, Tempero admits. Investigators at Johns Hopkins University School of Medicine have been looking at an autologous cell-based vaccine. Antigen-specific vaccines are in development in pancreatic cancer as well, Tempero says.

There is a need to “make room” for immunotherapies and determine their optimal use, especially with regard to immune checkpoint inhibitors, such as PD-1 and anti-CTLA-4.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x